📰 Solid Tumors News
Page 13 - Solid Tumors News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Solid Tumors. Real-time updates on events, politics, business and more.
April 18, 2024
Two immune checkpoint inhibitors are being evaluated together in a phase 1 trial for certain patients with advanced solid tumors.
April 12, 2024
Experts discuss the importance of NGS testing for identifying actionable alterations like RET fusions in solid tumors and when to consider testing.
April 8, 2024
LOS ALTOS - RenovoRx, Inc. , a clinical-stage biopharmaceutical company developing novel precision oncology therapies based on a local drug-delivery platform, today announced that Shaun Bagai,...
April 8, 2024
Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology and other major diseases, announces that preclinical data on multiple novel bispecific antibodies as well as antibody-drug-conjugates (ADCs) from its oncology pipeline are presented at the American Association for Cancer Research (AACR) Ann...
April 8, 2024
VANCOUVER, British Columbia, April 08, 2024 -- Zymeworks Inc. , a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the...
April 6, 2024
Press Release ENHERTU® Approved in the U.S. as First Tumor Agnostic HER2 Directed Therapy for Previously Treated Patients with Metastatic HER2...
April 4, 2024
Immunocore to present at upcoming investor conferences Immunocore Holdings plc , a commercial-stage biotechnology company pioneering and delivering transformative immunomodulating medicines to...
April 2, 2024
Corporate Presentation April 2024 www.nucana.com Disclaimer ...
March 26, 2024
One of the building blocks for newly launched Clasp Therapeutics Corp. is making the right patient choices for treatment. If those who receive the company’s therapy are correctly identified, CEO Robert Ross told BioWorld, it will have a profound effect on outcomes. The missing link in cancer treatment, Ross added, was how to identify a patient, something he said Clasp is able to do.